ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02227459
Recruitment Status : Completed
First Posted : August 28, 2014
Last Update Posted : May 11, 2017
Sponsor:
Collaborator:
This trial was conducted by the previous sponsor, Nitto Denko
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of multiple doses of ND-L02-s0201 in subjects with moderate to extensive hepatic fibrosis.

Condition or disease Intervention/treatment Phase
Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4) Drug: ND-L02-s0201 Injection Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection, A Vitamin A-coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Subjects With Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Study Start Date : October 2014
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental: Arm A
Once a week dosing
Drug: ND-L02-s0201 Injection
Other Name: BMS-986263

Experimental: Experimental: Arm B
Twice a week dosing
Drug: ND-L02-s0201 Injection
Other Name: BMS-986263




Primary Outcome Measures :
  1. Number of participants with serious and non-serious adverse events [ Time Frame: After treatment for 5 consecutive weeks and follow-up through week 24 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female between 18 and 75 years
  2. Diagnosis of METAVIR F3-4 hepatic fibrosis determined by liver biopsy done within 12 months before screening (Cohort 1) or at the pre-dose biopsy within 6 weeks before treatment (Cohorts 2 and 3)
  3. Adequate and stable synthetic hepatic function (albumin ≥ 3 g/dL, international normalized ratio [INR] ≤ 1.4 x upper limit of normal [ULN] and stable by prior medical history).
  4. Adequate and stable hepatic function as measured by alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase (AST), gamma glutamate transferase (GGTP), and total bilirubin (ALT/AST ≤ 5 x ULN, ALP ≤ 4 x ULN, GGTP ≤ 4 x ULN, bilirubin ≤ 2x ULN and stable by prior medical history).
  5. Platelet count ≥ 75,000/mm3, hemoglobin ≥ 10 g/dL, and white blood cell count (WBC) > 3000/µL.
  6. No signs of decompensated liver disease (ascites, hepatic encephalopathy, or variceal bleeding).
  7. No clinically significant abnormalities on 12-lead electrocardiogram (ECG).
  8. No other intercurrent medical conditions or infections considered clinically significant by the Investigator.
  9. Clinical laboratory assessments are within the laboratory limits of normal values or not considered clinically significant by the Investigator.
  10. Vitamin A levels at screening must be less than or equal to the upper limit of normal (ULN 95 µg/dL or 3.32 µmol/L).
  11. Any male subject, if sexually active, agrees to use barrier contraceptive techniques as defined in the protocol. If female, the subject must be of non-childbearing potential as defined in the protocol.
  12. Subjects who are active substances abusers may be enrolled at the discretion of the Principal Investigator.
  13. Willing and able to provide written informed consent and comply with the study procedures and visit schedule, including follow up visits.

Exclusion Criteria:

  1. Any disease or condition which, in the opinion of the Investigator, might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, skeletal, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism, or excretion of ND L02 s0201, or would place the subject at increased risk.
  2. On ongoing therapy for HCV/HBV, or received therapy for HCV/HBV within 12 weeks prior to administration of study drug.
  3. On interferon therapy for any disease or received interferon therapy for any disease within 12 weeks prior to administration of study drug.
  4. History of bone disease, including osteoporosis and osteomalacia, Paget's disease of bone, or a history of unexplained fractures or fractures after minimal trauma.
  5. Alpha-fetoprotein (AFP) ≥ 50 ng/mL or signs of abnormality or hepatocellular carcinoma on ultrasound survey of the liver.
  6. Carcinoembryonic antigen (CEA) levels above the ULN.
  7. Laboratory test results include abnormal values considered to be clinically significant by the Investigator.
  8. Participated in a concurrent interventional study with the last intervention occurring within 12 weeks prior to administration of study drug.
  9. Taken vitamin A or vitamin D supplements or multi-vitamins that contain vitamin A or vitamin D between the screening visit and administration of study drug.
  10. History, within the last 2 years, of alcohol abuse, significant mental illness, or physical dependence on any opioid.
  11. Veins unsuitable for repeated venipuncture or IV infusion (eg, veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).
  12. Received recent treatment with alternative therapies, which, in the opinion of the Investigator, could potentially confound clinical or laboratory assessments.
  13. Lost more than 500 mL of blood within 56 days prior to administration of study drug.
  14. Body mass index (BMI) > 38 kg/m2.
  15. History of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome-related illness (AIDS).
  16. History of malignancy within the last 5 years with the exception of basal cell carcinoma.
  17. Woman of childbearing potential.
  18. History of hypersensitivity to H2-receptor antagonists.
  19. Any other reason that, in the opinion of the Investigator or the Sponsor's Medical Monitor, makes the subject unsuitable for enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02227459


Locations
United States, Texas
Texas Liver Institute
Austin, Texas, United States, 78215
Bulgaria
Tokuda Hospital
Sofia, Bulgaria
Sponsors and Collaborators
Bristol-Myers Squibb
This trial was conducted by the previous sponsor, Nitto Denko
Investigators
Principal Investigator: Eric Lawitz, MD Texas Liver Institute
Principal Investigator: Rozalina Balabanska, MD Tokuda Hospital

Additional Information:
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT02227459     History of Changes
Other Study ID Numbers: ND-L02-s0201-002
First Posted: August 28, 2014    Key Record Dates
Last Update Posted: May 11, 2017
Last Verified: May 2017

Additional relevant MeSH terms:
Fibrosis
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases